In summary, angiogenesis, the formation of new blood vessels, is important in leukocyte extravasation and thus the pathogenesis of RA. The outcome of neovascularization highly depends on the imbalance between angiogenic and angiostatic mediators produced in the rheumatoid synovium. Therefore, angiogenesis research is important for the understanding of the pathogenesis of inflammatory arthritis. In addition, existing and potential angiostatic drugs may be useful for future therapy of RA.
Get full access to this article
View all access options for this article.
References
1.
Colville-NashPR, ScottDL.Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis1992;51:919–25.
FolkmanJ.Angiogenesis-retrospect and outlook. EXS1991;59:4–13.
7.
HarrisEDJr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med1990;332:1277–87.
8.
SzekaneczZ, HainesGK, LinTR, HarlowLA, GoerdtS, RayanG, KochAE.Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum1994;37:221–31.
9.
KochAE, BurrowsJC, HainesGK, CarlosTM, HarlanJ, LeibovichSJ.Immunolocalization of leukocyte and endothelial adhesion molecules in human rheumatoid and osteoarthritic synovial tissue. Lab Invest1991;64,313–20.
10.
AuerbachW, AuerbachR.Angiogenesis inhibition: a review. Pharmac Ther1994;63:265–311.
11.
Diaz-FloresL, GutierrezR, VarelaH.Angiogenesis: an update. Histol Histopathol1994;9:807–43.
12.
SchweigererL.Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med1995;73:497–508.
13.
MontesanoR, PepperMS, VassalliJ-D, OrciL.Modulation of angiogenesis in vitro. EXS1991;59:129–36.
14.
JacksonCJ, JenkinsK, SchrieberL.Possible mechanisms of type I collagen-induced vascular tube formation. EXS1992;59:198–204.
15.
SzekaneczZ, ShahMR, HarlowLA, PearceWH, KochAE.Interleukin-8 and tumor necrosis factor-alpha are involved in human aortic endothelial cell migration. Pathobiology1994; 62:134–39.
16.
SzekaneczZ, ShahMR, PearceWH, KochAE.Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4. Agents Actions1994;42:159–62.
17.
KochAE, HalloranMM, HaskellCJ, ShahMR, PolveriniPJ.Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature1995;376:517–9.
18.
LeibovichSJ, PolveriniPJ, ShepardHM, WisemanDM, ShivelyV, NuseirN.Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature1987;329:630–2.
19.
KochAE, PolveriniPJ, KunkelSL, HarlowLA, DiPietroLA, ElnerVM, ElnerSG, StrieterRM.Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science1992;258:1798–801.
HuDE, HoriY, FanT-PD. Interleukin-8 stimulates angiogenesis in rats. Inflammation1993;17:135–43.
22.
SanoH, ForoughR, MaierJAM, CaseJP, JacksonA, EnglekaK.Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol1990;110:1417–26.
23.
ByrdV, ZhaoXM, McKeehanWL, MillerGG, ThomasJW.Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum1996;39:914–22.
24.
QuZ, HuangXN, AhmadiP, AndresevicJ, PlanckSR, HartCE, RosenbaumJT.Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest1995;73:339–46.
25.
GoddardDH, GrossmanSL, WilliamsWV, WeinerDB, GrossJL, EidsvoogK.Regulation of synovial cell growth: coexpression of transforming growth factor ß and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum1992;35:1296–303.
26.
HosakaS, ShahMR, BarquinN, HainesGK, KochAE.Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology1995;63:249–56.
27.
SunderkötterC, SteinbrinkK, GoebelerM, BhardwajR, SorgC.Macrophages and angiogenesis. J Leukoc Biol1994;55:410–22.
28.
KochAE, HarlowLA, HainesGK, AmentoEP, UnemoriEN, WongWL, PopeRM, FerraraN.Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol1994;152:4149–56.
29.
FavaRA, OlsenNJ, Spencer-GreenG, YeoKT, YeoTK, BerseB, JackmanRW, SengerDR, DvorakHF, BrownLF.Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med1994;180:341–6.
30.
NagashimaM, YoshinoS, IshiwataT, AsanoG.Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol1995;22:1624–30.
31.
RosenEM, GrantDS, KleinmanHK, GoldbergID, BhargavaMM, NickoloffBJ, KinsellaJL, PolveriniP.Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol1993;47P:227–34.
SatoN, BeitzJG, KatoJ, YamamotoM, ClarkJW, CalabresiP, FrackeltonARJr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol1993;142:1119–30.
35.
RemmersEF, SanoH, WilderRL.Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Sem Arthritis Rheum1991;21:191–9.
OikawaT, OnozawaC, SakaguchiM, MoritaI, MurotaS.Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull1994;17:1686–8.
38.
RisauW, DrexlerH, MironovV, SmitsA, SiegbahnA, FunaK, HeldinCH.Platelet-derived growth factor is angiogenic in vivo. Growth Factors1992;7:261–6.
LafyatisR, RemmersEF, RobertsAB, YocumDE, SpornMB, WilderRL.Anchorage-independent growth of synoviocytes from arthritic and normal joints. J Clin Invest1989;83:1267–76.
41.
TakeuchiM, OtsukaT, MatsuiN, AsaiK, HiranoT, MoriyamaA.Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum1994;37:662–72.
42.
KusadaJ, OtsukaT, MatsuiN, HiranoT, AsaiK, KatoT.Immuno-reactive human epidermal growth factor (h-EGF) in rheumatoid synovial fluids. Nippon Seikeigeka Gakkai Zasshi1993;67:859–65.
43.
MatsumotoT, GargoskySE, IwasakiK, RosenfeldRG.Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab1996;81:150–5.
44.
KeyszerGM, HeerAH, KriegsmannJ, GeilerT, KeysserC, GayRE, GayS: Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol1995;22:275–81.
45.
WisemanDM, PolveriniPJ, KampDW, LeibovichSJ.Transforming growth factor-beta (TGFß) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun1988;157:793–800.
46.
WrightJK, CawstonTE, HazlemanBL.Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta1991;1094:207–10.
47.
HamiltonJA, PiccoliDS, LeizerT, ButlerDM, CroattoM, RoystonAK.Transforming growth factor beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostaglandin E2 production, in human synovial fibroblasts. Proc Natl Acad Sci USA1991;88:7180–4.
48.
ChuCQ, FieldM, AbneyE, ZhengRQH, AllardS, FeldmannM, MainiRN.Transforming growth factor-B1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol1991;86:380–6.
49.
SzekaneczZ, HainesGK, HarlowLA, ShahMR, FongTW, FuR, LinSJ-W, RayanG, KochAE.Increased synovial expression of transforming growth factor (TGF)-ß receptor endoglin and TGF-B1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol1995;76:187–94.
50.
BuchtA, LarssonP, WeisbrotL, ThorneC, PisaP, SmedegardG, KeystoneEC, GronbergA.Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol1996;103:357–67.
51.
WahlSM, AllenJB, WongHL, DoughertySF, EllingsworthLR.Antagonistic and agonistic effects of transforming growth factor-ß and IL-1 in rheumatoid synovium. J Immunol1990;145:2514–9.
52.
FavaRA, OlsenNJ, PostlethwaiteAE, BroadleyKN, DavidsonJM, NanneyLB.Transforming growth factor ß1 (TGF-β1) induced neutrophil recruitment to synovial tissues: Implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med1991;173:1121–32.
53.
BrandesME, AllenJB, OgawaY, WahlSM.Transforming growth factor ß1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest1991;87:1108–13.
54.
AngiolilloAL, KaneganeH, SgadariC, ReamanGH, TosatoG.Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun1997;233:231–7.
55.
HalloranMM, HaskellCJ, WoodsJM, HosakaS, KochAE.Interleukin-13 is an endothelial chemotaxin. Pathobiology, in press.
56.
KochAE, KunkelSL, BurrowsJC, EvanoffHL, HainesGK, PopeRM, StrieterRM.The synovial tissue macrophage as a source of the chemotactic cytokine interleukin-8. J Immunol1991;147:2187–95.
57.
KochAE, PolveriniPJ, LeibovichSJ.Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum1986;29:471–9.
58.
YoshidaS, OnoM, ShonoT, IzumiH, IshibashiT, SuzukiH, KuwanoM.Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol1997;17:4015–23.
59.
SaxneT, PalladinoMAJr., HeinegardD, TalalN, WollheimFA.Detection of tumor necrosis factor a but not tumor necrosis factor ß in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum1988:31:1041–5.
60.
TettaC, CamussiG, ModenaV, Di VittorioC, BaglioniC.Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Annals Rheum Dis1990;49:665–7.
61.
LupiaE, MontrucchioG, BattagliaE, ModenaV, CamussiG.Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol1996;26:1690–4.
62.
SzekaneczZ, SzegediG, KochAE.Cellular adhesion molecules in rheumatoid arthritis. Regulation by cytokines and possible clinical importance. J Investig Med1996;44:124–35.
63.
AbbotSE, KaulA, StevensCR, BlakeDR.Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression. Arthritis Rheum1992;35:401–6.
64.
LindsleyHB, SmithDD, DavisLS, KochAE, LipskyPE.Regulation of the expression of adhesion molecules by human synoviocytes. Semin Arthritis Rheum1992;21:330–4.
FeldmannM, BrennanFM, MainiRN.Role of cytokines in rheumatoid arthritis. Annu Rev Immunol1996;14:397–440.
67.
ShoreA, JaglalS, KeystoneEC.Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol1986;65:293–302.
68.
MotroB, ItinA, SachsL, KeshetE.Pattern of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA1990;87:3092–6.
SachsL.Angiogenesis-cytokines as part of a network. EXS1991:59:20–2.
71.
HoussiauFA, DevogelaerJ-P, Van DammeJ, De DeuxchaisnesCN, Van SnickJ.Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum1988;31:784–8.
72.
GuerneP-A, ZurawBL, VaughanJH, CarsonDA, LotzM.Synovium as a source of interleukin 6 in vitro. J Clin Invest1989;83:585–92.
73.
FieldM, ChuC, FeldmannM, MainiRN.Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int1991;11:45–50.
74.
IsomakiP, LuukkainenR, ToivanenP, PunnonenJ.The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum1996;39:1693–1702.
75.
WoodsJM, HainesGK, ShahMR, KochAE.Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis. Arthritis Rheum1996;39:S129.
76.
McInnesIB, Al-MughalesJ, FieldM, LeungBP, HuangF, DixonR, SturrockRD, WilkinsonPC, LiewFY.The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med1996;2:175–82.
77.
Alvaro-GarciaJM, ZvaiflerNJ, FiresteinGS.Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med1989;170:865–75.
78.
StrieterRM, KunkelSL, ShanafeltAB, ArenbergDA, KochAE, PolveriniPJ.The role of C-X-C chemokines in regulation of angiogenesis. In: KochAE, StrieterRM, eds. Chemokines in disease. Austin: R.G. Landes Company, 1996;195–209.
79.
KochAE, KunkelSL, StrieterRM.Chemokines in arthritis. In: KochAE, StrieterRM, eds. Chemokines in disease. Austin: R.G. Landes Company, 1996;103–16.
80.
StrieterRM, PolveriniPJ, KunkelSL, ArenbergDA, BurdickMD, KasperJ, DzuibaJ, Van DammeJ, WalzA, MarriottD, ChanS-Y, RoczniakS, ShanafeltAB.The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem1995;270:27348–57.
81.
SmithDR, PolveriniPJ, KunkelSL, OrringerMB, WhyteRI, BurdickMD, WilkeCA, StrieterRM.Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med1994;179:1409–15.
82.
HosakaS, AkahoshiT, WadaC, KondoH.Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol1994;97:451–7.
83.
RampartM, HermanAG, GrilletB, OpdenakkerG, Van DammeJ.Development and application of a radioimmunoassay for interleukin-8: Detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab Invest1992;66:512–8.
84.
KochAE, KunkelSL, HarlowLA, MazarakisDD, HainesGK, BurdickMD, PopeRM, WalzA, StrieterRM.Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest1994;94:1012–8.
85.
KochAE, KunkelSL, ShahMR, HosakaS, HalloranMM, HainesGK, BurdickMD, PopeRM, StrieterRM.Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol1995;155:3660–6.
86.
HoganM, SherryB, RitchlinC, FabreM, WinchesterR, CeramiA, BucalaR.Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. Cytokine1994;6: 61–9.
87.
CastorCW, AndrewsPC, SwartzRD, EllisSC, HosslerPA, ClarkMR, MattesonEL, SachterEF.The origin, variety, distribution and biological fate of connective tissue activating peptide III isoforms: characteristics in patients with rheumatoid, renal, and arterial disease. Arthritis Rheum1993;36:1142–53.
88.
IsikFF, RandRP, GrussJS, BenjaminD, AlpersCE.Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res1996;61:71–6.
89.
GongJH, RatkayLG, WaterfieldJD, Clark-LewisI.An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med1997;186:131–7.
90.
KochAE, KunkelSL, HarlowLA, JohnsonB, EvanoffHL, HainesGK, BurdickMD, StrieterRM.Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest1992;90:772–9.
91.
CanfieldAE, SchorAM.Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci1995;108:797–809.
92.
NicosiaRF, BonannoE, SmithM.Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol1993;154:654–61.
93.
GambleJR, MatthiasLJ, MeyerG, KaurP, RussG, FaullR, BerndtMC, VadasMA.Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol1993;121:931–43.
94.
MaedaS, SawaiT, UzukiM, TakahashiY, OmotoH, SekiM, SakuraiM.Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis1995;54:970–5.
95.
YoshiharaY, ObataK, FujimotoN, YamashitaK, HayakawaT, ShimmeiM.Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum1995;38:969–75.
96.
HembryRM, BaggaMR, ReynoldsJJ, HamblenDL.Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis1995;54:25–32.
97.
SzekaneczZ, HainesGK, KochAE.Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol1997;50:314–9.
98.
BelcherC, FawthropF, BunningR, DohertyM.Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis1996:55:230–6.
99.
RondayHK, SmitsHH, Van MuijenGN, PruszczynskiMS, DolhainRJ, Van LangelaanEJ, BreedveldFC, VerheijenJH.Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol1996;35:416–23.
100.
HaskardDO.Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol1995;7:229–34.
101.
SaikiI, MurataJ, MakabeT, NishiN, TokuraS, AzumaI.Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). Jpn J Cancer Res1990;81:668–75.
102.
NicosiaRF, BonannoE.Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am J Pathol1991;138:829–33.
103.
AlbeldaSM.Differential expression of integrin cell-substratum adhesion receptors on endothelium. EXS1991;59:188–92.
104.
AlbeldaSM, BuckCA.Integrins and other cell adhesion molecules. FASEB J1990;4:2868–80.
105.
SzekaneczZ, SzegediG.Cell adhesion receptors: structure, function and clinical aspects. Orv Hetil1992;133:135–42.
106.
LuscinskasFW, LawlerJ.Integrins as dynamic regulators of vascular function. FASEB J1994;8:929–38.
107.
BrooksPC, ClarkRA, ChereshDA.Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science1994;264:569–71.
108.
BischoffJ.Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol1995;5:69–74.
109.
BauerJ, MargolisM, SchreinerC, EdgellCJ, AzizkhanJ, LazarowskiE, JulianoRL.In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J Cell Physiol1992;153: 437–49.
110.
El GabalawyH, WilkinsJ.Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: an immunohistologic study of distribution patterns. J Rheumatol1993;20:231–7.
111.
JohnsonB, HainesGK, HarlowLA, KochAE.Adhesion molecule expression in human synovial tissues. Arthritis Rheum1993;36:137–46.
112.
NguyenM, StrubelNA, BischoffJ.A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature1993;365:267–9.
113.
HorakER, LeekR, KlenkN, LeJeuneS, SmithK, StuartN, GreenallM, StepniewskaK, HarrisAL.Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet1992;340:1120–4.
114.
MaierJA, DeliaD, ThorpePE, GaspariniG.In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antiody TEC-11. Anticancer Drugs1997;8:238–44.
115.
KumarP, WangJM, BernabeuC.CD 105 and angiogenesis [editorial]. J Pathol1996;178:363–6.
116.
WilkinsonLS, EdwardsJCW, PostonRN, HaskardDO.Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest1993;68:82–8.
117.
SzekaneczZ, HainesGK, HarlowLA, ShahMR, FongTW, FuR, LinSJ-W, KochAE.Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin Immunol Immunopathol1995;76:180–6.
118.
CamussiG, MontrucchioG, LupiaE, De MartinoA, PeronaL, AreseM, VercelloneA, TonioloA, BussolinoF.Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol1995;154:6492–501.
119.
HilliquinP, GuinotP, Chermat-IzardV, PuechalX, MenkesCJ.Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol1995;22:1651–4.
120.
MenkesCJ, RenouxM, LaoussadiS, MauborgneA, BruxelleJ, CesselinF.Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol1993;20:714–7.
121.
Frater-SchroderM, RisauW, HallmannR, GautschiP, BohlenP.TNFa, a potent inhibitor of cell growth in vitro is angiogenic in vivo. Proc Natl Acad Sci USA1987;84:5277–81.
122.
van RoonJA, van RoyJL, Gmelig-MeylingFH, LafeberFP, BijlsmaJW.Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum1996;39:829–35.
123.
SugiyamaE, KurodaA, TakiH, IkemotoM, HoriT, YamashitaN, MaruyamaM, KobayashiM.Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol1995;22:2020–6.
124.
KochAE, FongTW, VolpertOV, HalloranMM, BouckNP.Interleukin-4 is an inhibitor of angiogenesis. Arthritis Rheum1996:39:S304.
125.
VoestEE, KenyonBM, O'ReillyMS, TruittG, D'AmatoRJ, FolkmanJ.Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst1995;87:581–6.
126.
AngiolilloA, SgadariC, TosatoG.A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci1996;795:158–67.
127.
SchlaakJF, PfersI, Meyer Zum BuschenfeldeKH, Marker HermannE.Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol1996;14:155–62.
128.
TanabeBK, AbeLM, KimuraLH, ReinkerKA, YamagaKM.Cytokine mRNA repertoire of articular chondrocytes from arthritic patients, infants, and neonatal mice. Rheumatol Int1996;16:67–76.
WaringPM, CarrollGJ, KandiahDA, BuirskiG, MetcalfD.Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthtitis Rheum1993;36:911–5.
131.
HamiltonJA, WaringPM, FilonziEL.Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-a. J Immunol1993;150:1496–502.
132.
VilligerPM, GengY, LotzM.Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest1993;91:1575–81.
133.
AngiolilloAL, SgadariC, TaubDD, LiaoF, FarberJM, MaheshwariS, KleinmanHK, ReamanGH, TosatoG.Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med1995;182:155–62.
134.
StrieterRM, KunkelSL, ArenbergDA, BurdickMD, PolveriniPJ.Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun1995;210:51–7.
135.
NarumiS, TominagaY, TamaruM, ShimaiS, OkumuraH, NishiojiK, ItohY, OkanoueT.Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol1997;158:5536–44.
136.
WooleyPH, SchaeferC, WhalenJD, DutcherJA, CountsDF.A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol1997;24:890–8.
137.
KochAE, FriedmanJ, BurrowsJC, HainesGK, BouckNP.Immunolocalization of the angiogenesis inhibitor thrombospondin in human arthritic synovial tissues. Pathobiology1993;161:1–6.
DameronKM, VolpertOV, TainskyMA, BouckN.Control of angiogenesis in fibroblasts by p53 regualtion of thrombospondin-1. Science1994;265:1582–4.
140.
DiPietroLA, NebgenDR, PolveriniPJ.Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res1994;31:178–85.
141.
KochAE, SzekaneczZ, FriedmanJ, HainesGK, LangmanCB, BouckNP.Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol, in press.
142.
HirataS, MatsubaraT, SauraR, TateishiH, HirohataK.Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum1989;32:1065–73.
143.
FiresteinGS, PaineMM, BoyleDL.Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum1994;37:193–200.
144.
KochAE, BurrowsJ, ChoM, PolveriniPJ, LeibovichSJ.Thiol containing compounds inhibit the production of macrophage-derived angiogenic activity. Agents Actions1991;34:350–7.
145.
KochAE, ChoM, BurrowsJ, LeibovichSJ, PolveriniPJ.Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun1988;154:205–12.
146.
SauraR, MatsubaraT, MizunoK.Inhibition of neovascularization in vivo by gold compounds. Rheumatol Int1994;14:1–7.
147.
OliverSJ, ChengTP, BanquerigoML, BrahnE.Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol1995;166:196–206.
148.
JosefssonE, TarkowskiA.Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum1997;40:154–63.
149.
Colville-NashPR, El-GhazalyM, WilloughbyDA.The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation. Agents Actions1993:38:126–34.
150.
IngberD, FujitaT, KishimotoS, SudoK, KanamaruT, BremH, FolkmanJ.Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature1990;348:555–7.
OliverSJ, BanquerigoML, BrahnE.Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol1994;157:291–9.
SewellKL, BreedveldF, FurrieE, O'BrienJ, BrinckerhoffC, Dynesius-TrenthamR, NosakaY, TrenthamDE.The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol1996;167:195–204.
155.
TrenthamDE, Dynesius-TrenthamRA.Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Rheum Dis Clin North Am1995;21:817–34.
156.
KloppenburgM, BreedveldFC, TerwielJP, MalleeC, DijkmansBA.Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum1994;37:629–36.
CarlsonRP, BaederWL, CacceseRG, WarnerLM, SehgalSN.Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann NY Acad Sci1993;685P:86–113.
159.
NemotoK, MaeT, AbeF, TakeuchiT.Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice. Ann NY Acad Sci1993;685P:148–54.
160.
MosesMA.A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol1993;8(11 Suppl):67S–69S.
161.
NakamuraS, KamihagiK, SatakedaH, KatayamaM.Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage: increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum1996;39:539.
van Dinther-JanssenACHM, HorstE, KoopmanG, NewmannW, ScheperRJ, MeijerCJ, PalsST.The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol1991;147:4207–10.
164.
MicanJM, MetcalfeDD.Arthritis and mast cell activation. J Allergy Clin Immunol1990;86:677–83.
165.
KochAE, KunkelSL, StrieterRM.Cytokines in rheumatoid arthritis. J Investig Med1995;43:28–38.
166.
ElicesMJ, TsaiV, StrahlD, GoelAS, TollefsonV, ArrheniusT, WaynerEA, GaetaFC, FikesJD, FiresteinGS.Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest1994;93:405–16.
167.
KochAE, TurkiewiczW, HarlowLA, PopeRM.Soluble E-selectin in arthritis. Clin Immunol Immunopathol1993;69:29–35.
168.
WellicomeSM, KapahiP, MasonJC, LebranchuY, YarwoodH, HaskardDO.Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol1993;92:412–8.
169.
RathanaswamiP, HachichaM, WongWL, SchallTJ, McCollSR.Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. Arthritis Rheum1993;36:1295–304.
170.
PrestaM, RusnatiM, UrbinatiC, TanghettiE, StatutoM, PozziA, GualandrisA, RagnottiG.Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. EXS1991;59;205–9.
171.
Martel-PelletierJ, McCollumR, FujimotoN, ObataK, CloutierJM, PelletierJP.Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest1994;70:807–15.
172.
MainiRN, ElliottMJ, BrennanFM, WilliamsRO, ChuCQ, PaleologE, CharlesPJ, TaylorPC, FeldmannM.Monoclonal anti-TNF- a antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev1995;144:195–221.
173.
KingsleyG, PanayiG, LanchburyJ.Immunotherapy of rheumatic diseases-practice and prospects. Immunol Today1991;12:177–9.
174.
MorelandLW, BaumgartnerSW, SchiffMH, TindallEA, FleischmannRM, WeaverAL, EttlingerRE, CohenS, KoopmanWJ, MohlerK, WidmerMB, BloschCM.Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein. N Engl J Med1997;337:141–147.
175.
ArendWP.Cytokine inhibitors and receptor antagonists. In: RichRR, FleisherTA, SchwartzBD, ShearerWT, StroberW, eds. Clinical immunology. Principles and practice. St. Louis: Mosby, 1996; 2046–55.
176.
DrevlowBE, LovisR, HangR, HaagMA, SinacoreJM, JacobsC, BloscheC, LandayA, MorelandLW, PopeRM.Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum1996;39:257–65.
177.
EvansCH, RobbinsPD.Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol1996;8:230–24.
178.
WahlSM, AllenJB, HinesKL, ImamichiT, WahlAM, FurchtLT, McCarthyJB.Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest1994;94:655–62.
179.
CorkillMM, KirkhamBW, HaskardDO, BarbatisC, GibsonT, PanayiGS.Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol1991;18:1453–60.
180.
BennettCF, CondonTP, GrimmS, ChanH, ChiangM-Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol1994;152:3530–40.
